16552-65-1

Usage

Uses

Used in Chemical Research:
5-Isoquinolinamine,4-bromo-(9CI) is used as a research chemical for various chemical studies and experiments. Its unique properties, such as the presence of a bromine atom, make it a valuable compound for exploring new synthetic pathways and understanding its reactivity with other chemicals.
Used in Pharmaceutical Industry:
5-Isoquinolinamine,4-bromo-(9CI) is used as an intermediate in the synthesis of pharmaceutical compounds. Its structural features allow it to be a key component in the development of new drugs, potentially leading to advancements in medicine and healthcare.
Used in Material Science:
5-Isoquinolinamine,4-bromo-(9CI) is used as a component in the development of new materials with specific properties. Its chemical structure can contribute to the creation of materials with tailored characteristics, such as improved stability or reactivity, for various applications in material science.
Used in Industrial Applications:
5-Isoquinolinamine,4-bromo-(9CI) is used as a raw material in the production of various industrial products. Its versatility in chemical reactions and synthesis makes it a valuable resource for the manufacturing of a wide range of products, from chemicals to consumer goods.

InChI:InChI=1/C9H7BrN2/c10-7-5-12-4-6-2-1-3-8(11)9(6)7/h1-5H,11H2

Upstream product

• 58142-46-4 4-bromo-5-nitro-isoquinoline 
• 21364-46-5 isoquinoline hydrochloride 
• 1532-97-4 4-bromoisoquinoline 
• 119-65-3 isoquinoline 

Downstream Products

• 651310-41-7 4-bromo-5-hydroxyisoquinoline 
• 1256787-17-3 4-bromo-5-chloroisoquinoline 
• 127625-94-9 4-bromo-5-isoquinolinesulphonyl chloride 
• 127625-93-8 4-bromo-5-isoquinolinesulphonamide 
• 808125-39-5 5-amino-4-vinylisoquinoline 

Relevant academic research and scientific papers

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors

Compound corresponding to general formula (I): [image] in which, R1 represents a hydrogen or halogen atom, an NH2, NHR2, NHCOR2, NO2, CN, CH2NH2 and CH2NHR2; or alternatively R1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substituted phenyl group or an optionally substituted heteroaromatic group; n represents 0, 1, 2 or 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Application in therapy.

NITROGENEOUS TRICYCLIC COMPOUND

A novel compound represented by the following formula (1) [wherein R1, R5, R6, R7, and R8 each represents hydrogen, halogeno, hydroxy, alkyl, alkenyl, etc.; X1···X2 represents -C

Nitrogen-containing tricyclic compounds

A novel compound represented by the following formula (1) or a salt thereof [wherein R1, R5, R6, R7, and R8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group an

5-Substituted isoquinoline derivatives

A compound represented by the following formula (1) or a salt thereof: wherein R1 represents hydrogen atom, a halogen atom and the like; R2 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; and R3 represents —O—X—C(A1)(A11)—C(A2)(A2l)—N(A3l)(A3)(X represents propylene group etc., A11 and A21 represent hydrogen atom, or a C1-6 alkyl group, A31 represents a C1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A1, A2, and A3 represent hydrogen atom, a C1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

Tricyclic compound

A novel compound represented by the formula (1): [R1 represents hydrogen atom, chlorine atom, or hydroxyl group; X1 . . . X2 represents —CH(R2)—CH(R3)—, —CH(R2)—CH(R3)—CH(R4)—, etc.; R2to R4represent hydrogen atom, or an alkyl group; A1, A11, A2, and A21 represent hydrogen atom, or an alkyl group; Y represents —CH(A3)-, —CH(A3)-C(A4)(A41)-, —CH(A3)-C(A4)(A41)-C(A5)(A51)-, or a single bond; A3, A4, A41, A5, and A51 represent hydrogen atom, or an alkyl group; Z represents hydroxyl group, or —N(A6)(A61); A6 represents hydrogen atom, or an alkyl group, A61 represents hydrogen atom, an alkyl group, an aralkyl group, etc.; and groups in each of one or more combinations selected from the group consisting of combinations of A6 and A3, A6 and A4, A6 and A1, A6 and A2, A2 and A3, A2 and A4, A6 and A5, A3 and A1, and A5 and A1 may bind to each other to form a 5- or 6-membered ring], or a salt thereof, which potently inhibits the phosphorylation of myosin regulatory light chain.

Heterocyclic derivatives, their preparation and medicinal products containing them

Compounds are disclosed of formula: in which R1 represents a residue of formula STR1 X represents a hydrogen atom or an alkyl radical, Y represents a hydrogen atom or an alkyl or alkoxy radical, Z represents an alkyl radical, n is equal to 2 or 3, Het represents a substituted piperidino (substituted at the 4-position with a 1-indenylidene, 1-indenyl or 1-indanyl radical or with a chain --(CH2)m --R2 or =CH--R2), substituted 1,2,3,6-tetrahydro-1-pyridyl (substituted at the 4-position with a chain --(CH2)m --R2), m is equal to 1 or 2, and R2 represents an optionally substituted 2- or 3-indolyl radical, a 1- or 2-indanyl, 1- or 2-indenyl, an optionally substituted 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-2-yl radical, a 1,2,3,4-tetrahydro-3-quinolyl radical, an optionally substituted 1,2,3,4-tetrahydro-2-naphthyl radical or a 1-indolyl radical, their preparation and medicinal products containing them.